Immunotherapy in locally advanced HNSCC: is there still room for new agents?
According to GlobalData's high-prescriber survey, approximately 40% of LA HNSCC patients receive definitive chemoradiotherapy without surgery.
Therapy Area
FDA issues complete response letter to Replimune’s RP1 for melanoma
ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity
ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D
Non-invasive diagnostics in endometriosis: at the cusp of a turning point
ACC 2026: Baxdrostat lowers BP in uncontrolled hypertension
ACC 2026: Lorundrostat lowers BP but raises hyperkalemia risk
Merck’s strategic shift: acquires Terns for $6.7bn, targeting dominance in CML
